Kura Oncology Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Kura Oncology kazanç ve gelirin sırasıyla yıllık 21.5% ve 58.3% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 24.5% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde -68.1% olacağı tahmin edilmektedir.

Anahtar bilgiler

21.5%

Kazanç büyüme oranı

24.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	58.3%
Gelecekteki özkaynak getirisi	-68.1%
Analist kapsamı	Good
Son güncelleme	26 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

DB:KUR - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	150	-163	-1	41	12
12/31/2025	58	-187	-60	-33	14
12/31/2024	58	-153	-36	-33	13
9/30/2024	N/A	-198	-169	-169	N/A
6/30/2024	N/A	-182	-155	-155	N/A
3/31/2024	N/A	-168	-138	-138	N/A
12/31/2023	N/A	-153	-125	-125	N/A
9/30/2023	N/A	-143	-117	-117	N/A
6/30/2023	N/A	-140	-110	-109	N/A
3/31/2023	N/A	-137	-114	-114	N/A
12/31/2022	N/A	-136	-111	-110	N/A
9/30/2022	N/A	-135	-108	-107	N/A
6/30/2022	N/A	-133	-112	-110	N/A
3/31/2022	N/A	-132	-109	-108	N/A
12/31/2021	N/A	-130	-106	-105	N/A
9/30/2021	N/A	-124	-101	-99	N/A
6/30/2021	N/A	-114	-93	-92	N/A
3/31/2021	N/A	-101	-80	-79	N/A
12/31/2020	N/A	-90	-72	-70	N/A
9/30/2020	N/A	-81	-67	-65	N/A
6/30/2020	N/A	-74	-62	-61	N/A
3/31/2020	N/A	-68	-61	-60	N/A
12/31/2019	N/A	-63	-55	-55	N/A
9/30/2019	N/A	-61	-51	-51	N/A
6/30/2019	N/A	-60	-52	-52	N/A
3/31/2019	N/A	-60	-50	-50	N/A
12/31/2018	N/A	-60	-49	-49	N/A
9/30/2018	N/A	-55	-46	-46	N/A
6/30/2018	N/A	-49	N/A	-39	N/A
3/31/2018	N/A	-43	N/A	-33	N/A
12/31/2017	N/A	-35	N/A	-28	N/A
9/30/2017	N/A	-32	N/A	-28	N/A
6/30/2017	N/A	-30	N/A	-27	N/A
3/31/2017	N/A	-28	N/A	-27	N/A
12/31/2016	N/A	-28	N/A	-25	N/A
9/30/2016	N/A	-27	N/A	-24	N/A
6/30/2016	N/A	-26	N/A	-23	N/A
3/31/2016	N/A	-25	N/A	-21	N/A
12/31/2015	N/A	-23	N/A	-18	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: KUR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: KUR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: KUR önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: KUR şirketinin gelirinin (yıllık 58.3% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: KUR şirketinin gelirinin (yıllık 58.3% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: KUR 3 yıl içinde kârsız olması bekleniyor.

Kura Oncology Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Kura Oncology, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Kura Oncology, Inc. Appoints Michael Vasconcelles to Its Board of Directors

Kura Oncology Announces Fda Clearance of Ind Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (Gist)

Kura Oncology, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Now 20% undervalued

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 2500 Value Index

Insufficient new directors

New minor risk - Share price stability

Kura Oncology, Inc. Completes Enrollment of 85 Patients in the Phase 2 Portion of KOMET-001

Kura Oncology Completes Enrollment in Registration-Directed Trial of Ziftomenib in NPM1-Mutant AML

Kura Oncology, Inc. to Report Q1, 2024 Results on May 02, 2024

Kura Oncology, Inc. Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML

Now 21% undervalued

Kura Oncology, Inc., Annual General Meeting, Jun 05, 2024

Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma

Kura Oncology, Inc. Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia

Kura Oncology, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Kura Oncology, Inc. Reports Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

New major risk - Share price stability

Kura Oncology, Inc. announced that it expects to receive $150 million in funding from EcoR1 Capital, LLC

Kura Oncology, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Kura Oncology, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Kura Oncology, Inc. Announces First Patient Dosed in Fit-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806

Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASG12C Inhibitors in Non-Small Cell Lung Cancer

Kura Oncology Appoints Brian Powl as Chief Commercial Officer

Kura Oncology, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Kura Oncology, Inc. has completed a Follow-on Equity Offering in the amount of $99.999707 million.

Kura Oncology, Inc. Presents Late-Breaking Clinical Data for Menin Inhibitor Ziftomenib At 2023 European Hematology Association Congress

Kura Oncology, Inc. to Report Q1, 2023 Results on May 10, 2023

Kura Oncology, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Kura Oncology, Inc. Announces First Patients Dosed in Phase 2 Registration-Directed Trial of Ziftomenib in NPM1-Mutant Acute Myeloid Leukemia

Chief Medical Officer recently sold €56k worth of stock

Kura Oncology Announces FDA Clearance of IND Application for KO-2806, A Next-Generation Farnesyl Transferase Inhibitor

Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib

Kura Oncology, Inc. announced that it expects to receive $150.000003 million in funding from Bristol-Myers Squibb Company,

Kura Oncology, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Kura Oncology, Inc. Reports Preliminary Proof of Mechanism in Phase 1/2 Clinical Trial of Tipifarnib Plus Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Kura Oncology, Inc. Reports Preclinical Data Supporting Use of Tipifarnib to Prevent Emergence of Resistance to Osimertinib in Non-Small Cell Lung Cancer

Kura Oncology, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Announces Executive Changes

Kura Oncology, Inc. Receives FDA Authorization to Proceed with Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Kura Oncology, Inc. Doses First Patient in Phase 1/2 Clinical Trial of Tipifarnib in Combination with Alpelisib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. Reports Final Results from Phase 2 Study of Tipifarnib in T-Cell Lymphoma

Kura Oncology Provides Update on Phase 1b Study of KO-539 in Acute Myeloid Leukemia

Independent Director Robert Hoffman has left the company

Kura Oncology, Inc.(NasdaqGS:KURA) dropped from Russell 3000E Index

Kura Oncology Doses First Patient in Phase 1b Expansion Cohorts with Menin Inhibitor KO-539

New 90-day low: €22.00

Kura Oncology Receives FDA Breakthrough Therapy Designation for Tipifarnib in Head and Neck Squamous Cell Carcinoma

Kura Oncology, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day low: €24.40

Kura Oncology Presents First Clinical Data for Menin Inhibitor KO-539 At American Society of Hematology Annual Meeting

New 90-day high: €29.40

Kura Oncology, Inc. to Report Q3, 2020 Results on Nov 05, 2020

Kura Oncology, Inc. Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Ka Inhibitor in Head and Neck Squamous Cell Carcinoma

New 90-day high: €26.40

Kura Oncology, Inc. to Report Q1, 2020 Results on May 04, 2020

New 90-day high: €24.80

New 90-day high - €18.50

New 90-day high - €17.50

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin